Bladder Cancer Journal Club
BLADDER CANCER PAPER RANKINGS
|
Click above for landmark papers, peruse below for key papers
Bladder cancer overview, basic science, epidemiology
(cited by 861) Esrig, David, et al. "Accumulation of nuclear p53 and tumor progression in bladder cancer." New England Journal of Medicine 331.19 (1994): 1259-1264.
(cited by 634) Wu, Xue-Ru. "Urothelial tumorigenesis: a tale of divergent pathways." Nature Reviews Cancer 5.9 (2005): 713.
(cited by 291) Dalbagni, Guido, et al. "Genetic alterations in bladder cancer." Lancet (London, England) 342.8869 (1993): 469-471.
(cited by 286) Mitra, Anirban P., Ram H. Datar, and Richard J. Cote. "Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification." Journal of Clinical Oncology 24.35 (2006): 5552-5564.
(cited by 179) Negri, Eva, and Carlo La Vecchia. "Epidemiology and prevention of bladder cancer." Invasive Bladder Cancer. Springer, London, 2007. 1-14.
(cited by 166) Kamat, Ashish M., et al. "Bladder cancer." The Lancet 388.10061 (2016): 2796-2810.
(cited by 115) Wolff, Erika M., Gangning Liang, and Peter A. Jones. "Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer." Nature Reviews Urology 2.10 (2005): 502.
(cited by 29) Stadler, W. M., et al. "Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ-confined node-negative urothelial bladder cancer (UBC)." Journal of Clinical Oncology 27.15S (2009): 5017-5017.
(cited by 634) Wu, Xue-Ru. "Urothelial tumorigenesis: a tale of divergent pathways." Nature Reviews Cancer 5.9 (2005): 713.
(cited by 291) Dalbagni, Guido, et al. "Genetic alterations in bladder cancer." Lancet (London, England) 342.8869 (1993): 469-471.
(cited by 286) Mitra, Anirban P., Ram H. Datar, and Richard J. Cote. "Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification." Journal of Clinical Oncology 24.35 (2006): 5552-5564.
(cited by 179) Negri, Eva, and Carlo La Vecchia. "Epidemiology and prevention of bladder cancer." Invasive Bladder Cancer. Springer, London, 2007. 1-14.
(cited by 166) Kamat, Ashish M., et al. "Bladder cancer." The Lancet 388.10061 (2016): 2796-2810.
(cited by 115) Wolff, Erika M., Gangning Liang, and Peter A. Jones. "Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer." Nature Reviews Urology 2.10 (2005): 502.
(cited by 29) Stadler, W. M., et al. "Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ-confined node-negative urothelial bladder cancer (UBC)." Journal of Clinical Oncology 27.15S (2009): 5017-5017.
Bladder cancer pathology, tumor markers
(cited by 992) Sidransky, David, et al. "Identification of p53 gene mutations in bladder cancers and urine samples." Science 252.5006 (1991): 706-709.
(cited by 861) Esrig, David, et al. "Accumulation of nuclear p53 and tumor progression in bladder cancer." New England Journal of Medicine 331.19 (1994): 1259-1264.
(cited by 726) Neal, DavidE, et al. "Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours." The Lancet 325.8425 (1985): 366-368.
(cited by 286) Mitra, Anirban P., Ram H. Datar, and Richard J. Cote. "Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification." Journal of Clinical Oncology 24.35 (2006): 5552-5564.
(cited by 263) Grossman, H. Barton, et al. "A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer." The Journal of urology 178.1 (2007): 62-67.
(cited by 263) Chatterjee, Sunanda J., et al. "Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma." Journal of clinical oncology 22.6 (2004): 1007-1013.
(cited by 259) Grossman, H. Barton, et al. "Surveillance for recurrent bladder cancer using a point-of-care proteomic assay." Jama 295.3 (2006): 299-305.
(cited by 257) Lotan, Yair, et al. "Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy." J Clin Oncol 23.27 (2005): 6533-6539.
(cited by 187) Habuchi, Tomonori, et al. "Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers." Urology 66.6 (2005): 64-74.
(cited by 102) Culp, Stephen H., et al. "Refining patient selection for neoadjuvant chemotherapy before radical cystectomy." The Journal of urology 191.1 (2014): 40-47.
(cited by 80) Reuter VE. The pathology of bladder cancer. Urology 2006; 67(3 Suppl 1): 11-7; discussion 17-8.
(cited by 861) Esrig, David, et al. "Accumulation of nuclear p53 and tumor progression in bladder cancer." New England Journal of Medicine 331.19 (1994): 1259-1264.
(cited by 726) Neal, DavidE, et al. "Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours." The Lancet 325.8425 (1985): 366-368.
(cited by 286) Mitra, Anirban P., Ram H. Datar, and Richard J. Cote. "Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification." Journal of Clinical Oncology 24.35 (2006): 5552-5564.
(cited by 263) Grossman, H. Barton, et al. "A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer." The Journal of urology 178.1 (2007): 62-67.
(cited by 263) Chatterjee, Sunanda J., et al. "Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma." Journal of clinical oncology 22.6 (2004): 1007-1013.
(cited by 259) Grossman, H. Barton, et al. "Surveillance for recurrent bladder cancer using a point-of-care proteomic assay." Jama 295.3 (2006): 299-305.
(cited by 257) Lotan, Yair, et al. "Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy." J Clin Oncol 23.27 (2005): 6533-6539.
(cited by 187) Habuchi, Tomonori, et al. "Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers." Urology 66.6 (2005): 64-74.
(cited by 102) Culp, Stephen H., et al. "Refining patient selection for neoadjuvant chemotherapy before radical cystectomy." The Journal of urology 191.1 (2014): 40-47.
(cited by 80) Reuter VE. The pathology of bladder cancer. Urology 2006; 67(3 Suppl 1): 11-7; discussion 17-8.
Non muscle invasive low grade
(cited by 1126) Heney, Niall M., et al. "Superficial bladder cancer: progression and recurrence." The Journal of urology 130.6 (1983): 1083-1086.
**first multicenter, detailed analysis for this
(cited by 323) Au, Jessie L-S., et al. "Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial." Journal of the National Cancer Institute 93.8 (2001): 597-604.
(cited by 245) Lamm, Donald L., et al. "Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder." The Journal of urology 153.5 (1995): 1444-1450.
(cited by 121) Huncharek, Michael, et al. "Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials." Journal of clinical epidemiology 53.7 (2000): 676-680.
(cited by 118) Schrag, Deborah, et al. "Adherence to surveillance among patients with superficial bladder cancer." Journal of the National Cancer Institute 95.8 (2003): 588-597.
(cited by 61) Oosterlinck, Willem, et al. "Low-grade Ta (noninvasive) urothelial carcinoma of the bladder." Urology 66.6 (2005): 75-89.
**first multicenter, detailed analysis for this
(cited by 323) Au, Jessie L-S., et al. "Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial." Journal of the National Cancer Institute 93.8 (2001): 597-604.
(cited by 245) Lamm, Donald L., et al. "Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder." The Journal of urology 153.5 (1995): 1444-1450.
(cited by 121) Huncharek, Michael, et al. "Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials." Journal of clinical epidemiology 53.7 (2000): 676-680.
(cited by 118) Schrag, Deborah, et al. "Adherence to surveillance among patients with superficial bladder cancer." Journal of the National Cancer Institute 95.8 (2003): 588-597.
(cited by 61) Oosterlinck, Willem, et al. "Low-grade Ta (noninvasive) urothelial carcinoma of the bladder." Urology 66.6 (2005): 75-89.
NONmuscle invasive high grade
(CITED BY 1945) SYLVESTER, RICHARD J., ET AL. "PREDICTING RECURRENCE AND PROGRESSION IN INDIVIDUAL PATIENTS WITH STAGE TA T1 BLADDER CANCER USING EORTC RISK TABLES: A COMBINED ANALYSIS OF 2596 PATIENTS FROM SEVEN EORTC TRIALS." EUROPEAN UROLOGY 49.3 (2006): 466-477.
(CITED BY 1090) SYLVESTER RJ, VAN DER MEIJDEN AP, LAMM DL. INTRAVESICAL BACILLUS CALMETTE-GUERIN REDUCES THE RISK OF PROGRESSION IN PATIENTS WITH SUPERFICIAL BLADDER CANCER: A META-ANALYSIS OF THE PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS. J UROL 2002; 168(5):1964-70.
(CITED BY 1014) LAMM, DONALD L., ET AL. "MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY." THE JOURNAL OF UROLOGY 163.4 (2000): 1124-1129.
(CITED BY 565) COOKSON, MICHAEL S., ET AL. "THE TREATED NATURAL HISTORY OF HIGH RISK SUPERFICIAL BLADDER CANCER: 15-YEAR OUTCOME." THE JOURNAL OF UROLOGY 158.1 (1997): 62-67.
(CITED BY 562) HERR HW. THE VALUE OF A SECOND TRANSURETHRAL RESECTION IN EVALUATING PATIENTS WITH BLADDER TUMORS. J UROL 1999; 162(1):74-6.
(CITED BY 444) MALMSTRÖM, PER-UNO, ET AL. "AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF THE LONG-TERM OUTCOME OF RANDOMISED STUDIES COMPARING INTRAVESICAL MITOMYCIN C VERSUS BACILLUS CALMETTE-GUÉRIN FOR NON–MUSCLE-INVASIVE BLADDER CANCER." EUROPEAN UROLOGY 56.2 (2009): 247-256.
(CITED BY 410) HERR HW, SOGANI PC. DOES EARLY CYSTECTOMY IMPROVE THE SURVIVAL OF PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER TUMORS? J UROL 2001; 166(4): 1296-9.
(CITED BY 195) NIEDER, ALAN M., ET AL. "MANAGEMENT OF STAGE T1 TUMORS OF THE BLADDER: INTERNATIONAL CONSENSUS PANEL." UROLOGY 66.6 (2005): 108-125.
(CITED BY 184) STÖCKLE, MICHAEL, ET AL. "RADICAL CYSTECTOMY-OFTEN TOO LATE?." EUROPEAN UROLOGY 13 (1987): 361-367.
(CITED BY 179) HERR HW. RESTAGING TRANSURETHRAL RESECTION OF HIGH RISK SUPERFICIAL BLADDER CANCER IMPROVES THE INITIAL RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPY. J UROL 2005; 174(6): 2134-7.
(CITED BY 165) HERR HW, DONAT SM, DALBAGNI G. CAN RESTAGING TRANSURETHRAL RESECTION OF T1 BLADDER CANCER SELECT PATIENTS FOR IMMEDIATE CYSTECTOMY? J UROL 2007; 177(1): 75-9.
(CITED BY 127) DALBAGNI, GUIDO, ET AL. "CLINICAL OUTCOME IN A CONTEMPORARY SERIES OF RESTAGED PATIENTS WITH CLINICAL T1 BLADDER CANCER." EUROPEAN UROLOGY 56.6 (2009): 903-910.
(CITED BY 76) DINNEY, COLIN PN, ET AL. "RELATIONSHIP AMONG CYSTECTOMY, MICROVESSEL DENSITY AND PROGNOSIS IN STAGE T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDER." THE JOURNAL OF UROLOGY 160.4 (1998): 1285-1290.
(CITED BY 72) KULKARNI, GIRISH S., ET AL. "OPTIMAL MANAGEMENT OF HIGH-RISK T1G3 BLADDER CANCER: A DECISION ANALYSIS." PLOS MEDICINE 4.9 (2007): E284.
(CITED BY 58) ARENDS, TOM JH, ET AL. "RESULTS OF A RANDOMISED CONTROLLED TRIAL COMPARING INTRAVESICAL CHEMOHYPERTHERMIA WITH MITOMYCIN C VERSUS BACILLUS CALMETTE-GUÉRIN FOR ADJUVANT TREATMENT OF PATIENTS WITH INTERMEDIATE-AND HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER." EUROPEAN UROLOGY 69.6 (2016): 1046-1052.
(CITED BY 1090) SYLVESTER RJ, VAN DER MEIJDEN AP, LAMM DL. INTRAVESICAL BACILLUS CALMETTE-GUERIN REDUCES THE RISK OF PROGRESSION IN PATIENTS WITH SUPERFICIAL BLADDER CANCER: A META-ANALYSIS OF THE PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS. J UROL 2002; 168(5):1964-70.
(CITED BY 1014) LAMM, DONALD L., ET AL. "MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY." THE JOURNAL OF UROLOGY 163.4 (2000): 1124-1129.
(CITED BY 565) COOKSON, MICHAEL S., ET AL. "THE TREATED NATURAL HISTORY OF HIGH RISK SUPERFICIAL BLADDER CANCER: 15-YEAR OUTCOME." THE JOURNAL OF UROLOGY 158.1 (1997): 62-67.
(CITED BY 562) HERR HW. THE VALUE OF A SECOND TRANSURETHRAL RESECTION IN EVALUATING PATIENTS WITH BLADDER TUMORS. J UROL 1999; 162(1):74-6.
(CITED BY 444) MALMSTRÖM, PER-UNO, ET AL. "AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF THE LONG-TERM OUTCOME OF RANDOMISED STUDIES COMPARING INTRAVESICAL MITOMYCIN C VERSUS BACILLUS CALMETTE-GUÉRIN FOR NON–MUSCLE-INVASIVE BLADDER CANCER." EUROPEAN UROLOGY 56.2 (2009): 247-256.
(CITED BY 410) HERR HW, SOGANI PC. DOES EARLY CYSTECTOMY IMPROVE THE SURVIVAL OF PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER TUMORS? J UROL 2001; 166(4): 1296-9.
(CITED BY 195) NIEDER, ALAN M., ET AL. "MANAGEMENT OF STAGE T1 TUMORS OF THE BLADDER: INTERNATIONAL CONSENSUS PANEL." UROLOGY 66.6 (2005): 108-125.
(CITED BY 184) STÖCKLE, MICHAEL, ET AL. "RADICAL CYSTECTOMY-OFTEN TOO LATE?." EUROPEAN UROLOGY 13 (1987): 361-367.
(CITED BY 179) HERR HW. RESTAGING TRANSURETHRAL RESECTION OF HIGH RISK SUPERFICIAL BLADDER CANCER IMPROVES THE INITIAL RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPY. J UROL 2005; 174(6): 2134-7.
(CITED BY 165) HERR HW, DONAT SM, DALBAGNI G. CAN RESTAGING TRANSURETHRAL RESECTION OF T1 BLADDER CANCER SELECT PATIENTS FOR IMMEDIATE CYSTECTOMY? J UROL 2007; 177(1): 75-9.
(CITED BY 127) DALBAGNI, GUIDO, ET AL. "CLINICAL OUTCOME IN A CONTEMPORARY SERIES OF RESTAGED PATIENTS WITH CLINICAL T1 BLADDER CANCER." EUROPEAN UROLOGY 56.6 (2009): 903-910.
(CITED BY 76) DINNEY, COLIN PN, ET AL. "RELATIONSHIP AMONG CYSTECTOMY, MICROVESSEL DENSITY AND PROGNOSIS IN STAGE T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDER." THE JOURNAL OF UROLOGY 160.4 (1998): 1285-1290.
(CITED BY 72) KULKARNI, GIRISH S., ET AL. "OPTIMAL MANAGEMENT OF HIGH-RISK T1G3 BLADDER CANCER: A DECISION ANALYSIS." PLOS MEDICINE 4.9 (2007): E284.
(CITED BY 58) ARENDS, TOM JH, ET AL. "RESULTS OF A RANDOMISED CONTROLLED TRIAL COMPARING INTRAVESICAL CHEMOHYPERTHERMIA WITH MITOMYCIN C VERSUS BACILLUS CALMETTE-GUÉRIN FOR ADJUVANT TREATMENT OF PATIENTS WITH INTERMEDIATE-AND HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER." EUROPEAN UROLOGY 69.6 (2016): 1046-1052.
intravesical therapy
(cited by 1611) Morales, A_, D. Eidinger, and A. W. Bruce. "Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors." The Journal of urology 116.2 (1976): 180-182.
**first BCG treatment
(cited by 1106) Sylvester, Richard J., ADRIAN PM van der MEIJDEN, and Donald L. Lamm. "Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials." The Journal of urology 168.5 (2002): 1964-1970.
(cited by 384) Tolley, D. A., et al. "The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup." The Journal of urology 155.4 (1996): 1233-1238.
**RCT
**first BCG treatment
(cited by 1106) Sylvester, Richard J., ADRIAN PM van der MEIJDEN, and Donald L. Lamm. "Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials." The Journal of urology 168.5 (2002): 1964-1970.
(cited by 384) Tolley, D. A., et al. "The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup." The Journal of urology 155.4 (1996): 1233-1238.
**RCT
bcg refractory
(cited by 285) Herr, Harry W., et al. "Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression." The Journal of urology 141.1 (1989): 22-28.
(cited by 242) Steinberg, Gary, et al. "Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder." The Journal of urology 163.3 (2000): 761-767.
(cited by 178) Dalbagni, Guido, et al. "Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin–refractory transitional cell carcinoma of the bladder." Journal of clinical oncology 24.18 (2006): 2729-2734.
(108) O'Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004; 172(3): 888-93.
(cited by 242) Steinberg, Gary, et al. "Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder." The Journal of urology 163.3 (2000): 761-767.
(cited by 178) Dalbagni, Guido, et al. "Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin–refractory transitional cell carcinoma of the bladder." Journal of clinical oncology 24.18 (2006): 2729-2734.
(108) O'Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004; 172(3): 888-93.
Muscle invasive bladder cancer: cystectomy
(cited by 3029) Stein, John P., et al. "Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients." Journal of clinical oncology 19.3 (2001): 666-675.
(cited by 1387) Bricker, Eugene M. "Bladder substitution after pelvic evisceration." Surgical Clinics of North America 30.5 (1950): 1511-1521.
**description that is the standard ileal conduit
(cited by 838) Shabsigh, Ahmad, et al. "Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology." European urology 55.1 (2009): 164-176.
(cited by 525) Herr, Harry W., et al. "Surgical factors influence bladder cancer outcomes: a cooperative group report." Journal of clinical oncology 22.14 (2004): 2781-2789.
(cited by 498) Ghoneim, Mohamed A., et al. "Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases." The Journal of urology 158.2 (1997): 393-399.
(cited by 245) Clark, Peter E., et al. "Radical cystectomy in the elderly: comparison of clinical outcomes between younger and older patients." Cancer 104.1 (2005): 36-43.
(cited by 240) Camey, M. L. D. A. "L'enterocystoplastie avec cystoprostatectomie totale pour cancer de la vessie." Ann. Urol. 13 (1979): 114-123.
**showed urethral sphincter can be used to form a continent neobladder after cystoprostatectomy.
(cited by 186) Stein, John P., et al. "Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients." The Journal of urology 173.4 (2005): 1163-1168.
(cited by 174) Dotan, Zohar A., et al. "Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival." The Journal of urology 178.6 (2007): 2308-2313.
(cited by 112) Donat, S. Machele, et al. "Radical cystectomy in octogenarians—does morbidity outweigh the potential survival benefits?." The Journal of urology 183.6 (2010): 2171-2177.
(cited by 82) Stewart, M. "Urinary diversion and bowel cancer." Annals of the Royal College of Surgeons of England 68.2 (1986): 98.
**probably the final nail in the coffin of ureterosigmoidostomy
(cited by 53) Silver, David A., et al. "Ureteral carcinoma in situ at radical cystectomy: does the margin matter?." The Journal of urology 158.3 (1997): 768-771.
(cited by 1387) Bricker, Eugene M. "Bladder substitution after pelvic evisceration." Surgical Clinics of North America 30.5 (1950): 1511-1521.
**description that is the standard ileal conduit
(cited by 838) Shabsigh, Ahmad, et al. "Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology." European urology 55.1 (2009): 164-176.
(cited by 525) Herr, Harry W., et al. "Surgical factors influence bladder cancer outcomes: a cooperative group report." Journal of clinical oncology 22.14 (2004): 2781-2789.
(cited by 498) Ghoneim, Mohamed A., et al. "Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases." The Journal of urology 158.2 (1997): 393-399.
(cited by 245) Clark, Peter E., et al. "Radical cystectomy in the elderly: comparison of clinical outcomes between younger and older patients." Cancer 104.1 (2005): 36-43.
(cited by 240) Camey, M. L. D. A. "L'enterocystoplastie avec cystoprostatectomie totale pour cancer de la vessie." Ann. Urol. 13 (1979): 114-123.
**showed urethral sphincter can be used to form a continent neobladder after cystoprostatectomy.
(cited by 186) Stein, John P., et al. "Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients." The Journal of urology 173.4 (2005): 1163-1168.
(cited by 174) Dotan, Zohar A., et al. "Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival." The Journal of urology 178.6 (2007): 2308-2313.
(cited by 112) Donat, S. Machele, et al. "Radical cystectomy in octogenarians—does morbidity outweigh the potential survival benefits?." The Journal of urology 183.6 (2010): 2171-2177.
(cited by 82) Stewart, M. "Urinary diversion and bowel cancer." Annals of the Royal College of Surgeons of England 68.2 (1986): 98.
**probably the final nail in the coffin of ureterosigmoidostomy
(cited by 53) Silver, David A., et al. "Ureteral carcinoma in situ at radical cystectomy: does the margin matter?." The Journal of urology 158.3 (1997): 768-771.
muscle invasive bladder cancer: pelvic lymph node dissection
(cited by 449) Leissner, J., et al. "Extended Radical Lymphadenectomy in Patients With Urothelial Bladder Cancer:: Results of a Prospective Multicenter Study." The Journal of urology 171.1 (2004): 139-144.
(cited by 373) Poulsen, Asger L., Thomas Horn, and Kenneth Steven. "Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall." The Journal of urology 160.6 (1998): 2015-2020.
(cited by 307) Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; 169(3):943-5
(cited by 298) International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24(24): 3967-72.
(cited by 290) Dhar, Nivedita Bhatta, et al. "Outcome after radical cystectomy with limited or extended pelvic lymph node dissection." The Journal of urology 179.3 (2008): 873-878.
(cited by 196) Koppie, Theresa M., et al. "Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?." Cancer 107.10 (2006): 2368-2374.
(cited by 147) Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol 2007; 178(4 Pt 1):1218-23.
(cited 110) Wishnow, Kenneth I., et al. "Incidence, extent and location of unsuspected pelvic lymph node metastasis in patients undergoing radical cystectomy for bladder cancer." The Journal of urology 137.3 (1987): 408-409.
(cited by 373) Poulsen, Asger L., Thomas Horn, and Kenneth Steven. "Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall." The Journal of urology 160.6 (1998): 2015-2020.
(cited by 307) Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; 169(3):943-5
(cited by 298) International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24(24): 3967-72.
(cited by 290) Dhar, Nivedita Bhatta, et al. "Outcome after radical cystectomy with limited or extended pelvic lymph node dissection." The Journal of urology 179.3 (2008): 873-878.
(cited by 196) Koppie, Theresa M., et al. "Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?." Cancer 107.10 (2006): 2368-2374.
(cited by 147) Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol 2007; 178(4 Pt 1):1218-23.
(cited 110) Wishnow, Kenneth I., et al. "Incidence, extent and location of unsuspected pelvic lymph node metastasis in patients undergoing radical cystectomy for bladder cancer." The Journal of urology 137.3 (1987): 408-409.
muscle invasive bladder cancer: chemotherapy
(cited by 1648) Grossman, H. Barton, et al. "Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer." New England Journal of Medicine 349.9 (2003): 859-866.
(cited by 1053) Gabrilove, Janice L., et al. "Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium." New England Journal of Medicine 318.22 (1988): 1414-1422.
(cited by 508) Vale, C., and Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. "Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis." The Lancet 361.9373 (2003): 1927-1934.
(cited by 328) of Trialists, International Collaboration. "International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial." Journal of Clinical Oncology 29.16 (2011): 2171.
(cited by 311) Winquist, Eric, et al. "Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis." The Journal of urology 171.2 (2004): 561-569.
(cited by 299) Millikan, Randall, et al. "Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC." Journal of Clinical Oncology 19.20 (2001): 4005-4013.
(cite by 295) Malmstrom, Per-Uno, et al. "Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1." The Journal of urology 155.6 (1996): 1903-1906.
(cited by 292) Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48(2):189-199.
(cited by 209) Dash, Atreya, et al. "A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder: a retrospective experience." Cancer 113.9 (2008): 2471-2477.
(cited by 194) Herr, Harry W., et al. "Defining optimal therapy for muscle invasive bladder cancer." The Journal of urology 177.2 (2007): 437-443.
(cited by 175) Sherif, Amir, et al. "Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer-Nordic cystectomy trial 2." Scandinavian journal of urology and nephrology 36.6 (2002): 419-425.
(cited by 170) Donat, S. Machele, et al. "Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience." European urology 55.1 (2009): 177-186.
(cited by 169) Sherif, Amir, et al. "Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies." European urology 45.3 (2004): 297-303.
(cited by 112) Sylvester, R., and C. Sternberg. "The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why." Annals of Oncology 11.7 (2000): 851-856.
(cited by 88) Weight, Christopher J., et al. "Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder: a contemporary series." Cancer: Interdisciplinary International Journal of the American Cancer Society 115.4 (2009): 792-799.
(cited by 70) Finnbladder, Norwegian Bladder Cancer Study Group, et al. "Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial." The Lancet 354.9178 (1999): 533-540.
(cited by 1053) Gabrilove, Janice L., et al. "Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium." New England Journal of Medicine 318.22 (1988): 1414-1422.
(cited by 508) Vale, C., and Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. "Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis." The Lancet 361.9373 (2003): 1927-1934.
(cited by 328) of Trialists, International Collaboration. "International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial." Journal of Clinical Oncology 29.16 (2011): 2171.
(cited by 311) Winquist, Eric, et al. "Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis." The Journal of urology 171.2 (2004): 561-569.
(cited by 299) Millikan, Randall, et al. "Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC." Journal of Clinical Oncology 19.20 (2001): 4005-4013.
(cite by 295) Malmstrom, Per-Uno, et al. "Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1." The Journal of urology 155.6 (1996): 1903-1906.
(cited by 292) Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48(2):189-199.
(cited by 209) Dash, Atreya, et al. "A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder: a retrospective experience." Cancer 113.9 (2008): 2471-2477.
(cited by 194) Herr, Harry W., et al. "Defining optimal therapy for muscle invasive bladder cancer." The Journal of urology 177.2 (2007): 437-443.
(cited by 175) Sherif, Amir, et al. "Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer-Nordic cystectomy trial 2." Scandinavian journal of urology and nephrology 36.6 (2002): 419-425.
(cited by 170) Donat, S. Machele, et al. "Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience." European urology 55.1 (2009): 177-186.
(cited by 169) Sherif, Amir, et al. "Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies." European urology 45.3 (2004): 297-303.
(cited by 112) Sylvester, R., and C. Sternberg. "The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why." Annals of Oncology 11.7 (2000): 851-856.
(cited by 88) Weight, Christopher J., et al. "Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder: a contemporary series." Cancer: Interdisciplinary International Journal of the American Cancer Society 115.4 (2009): 792-799.
(cited by 70) Finnbladder, Norwegian Bladder Cancer Study Group, et al. "Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial." The Lancet 354.9178 (1999): 533-540.
muscle invasive bladder cancer: bladder sparing
(cited by 470) Shipley, W. U., et al. "Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03." Journal of Clinical Oncology 16.11 (1998): 3576-3583.
(cited by 385) Shipley, W. U., et al. "Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer." Urology 60.1 (2002): 62-67.
(cited by 265) Efstathiou, Jason A., et al. "Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience." European urology 61.4 (2012): 705-711.
(cited by 236) Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19(1): 89-93.
(cited by 227) Shariat, Shahrokh F., et al. "Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy." European urology 51.1 (2007): 137-151.
(cited by 210) Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16(4):1298-301.
(cited by 96) Montie JE. Against bladder sparing: surgery. J Urol. 1999; 162(2): 452-5.
(cited by 63) Harland, S. J., et al. "A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder." The Journal of urology 178.3 (2007): 807-813.
(cited by 55) Herr HW, Donat SM. Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. J Urol 1999; 161(6): 1854-7.
(cited by 385) Shipley, W. U., et al. "Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer." Urology 60.1 (2002): 62-67.
(cited by 265) Efstathiou, Jason A., et al. "Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience." European urology 61.4 (2012): 705-711.
(cited by 236) Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19(1): 89-93.
(cited by 227) Shariat, Shahrokh F., et al. "Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy." European urology 51.1 (2007): 137-151.
(cited by 210) Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16(4):1298-301.
(cited by 96) Montie JE. Against bladder sparing: surgery. J Urol. 1999; 162(2): 452-5.
(cited by 63) Harland, S. J., et al. "A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder." The Journal of urology 178.3 (2007): 807-813.
(cited by 55) Herr HW, Donat SM. Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. J Urol 1999; 161(6): 1854-7.
urinary diversion
(cited by 352) Madersbacher, Stephan, et al. "Long-term outcome of ileal conduit diversion." The Journal of urology 169.3 (2003): 985-990.
(cited by 296) Hautmann, Richard E., et al. "Long-term results of standard procedures in urology: the ileal neobladder." World journal of urology 24.3 (2006): 305-314.
(cited by 120) Studer, U. E., et al. "Summary of 10 years' experience with an ileal low-pressure bladder substitute combined with an afferent tubular isoperistaltic segment." World Journal of Urology 14.1 (1996): 29-39.
**studer orthotopic
(cited by 95) Stein, John P., et al. "Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer." The Journal of urology 181.5 (2009): 2052-2059.
(cited by 89) Hedgepeth, Ryan C., et al. "Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions." Urology 76.3 (2010): 671-675.
(cited by 296) Hautmann, Richard E., et al. "Long-term results of standard procedures in urology: the ileal neobladder." World journal of urology 24.3 (2006): 305-314.
(cited by 120) Studer, U. E., et al. "Summary of 10 years' experience with an ileal low-pressure bladder substitute combined with an afferent tubular isoperistaltic segment." World Journal of Urology 14.1 (1996): 29-39.
**studer orthotopic
(cited by 95) Stein, John P., et al. "Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer." The Journal of urology 181.5 (2009): 2052-2059.
(cited by 89) Hedgepeth, Ryan C., et al. "Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions." Urology 76.3 (2010): 671-675.
advanced bladder cancer
(cited by 1148) Rosenberg, Jonathan E., et al. "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial." The Lancet 387.10031 (2016): 1909-1920.
(cited by 1093) von der Maase, Hans, et al. "Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer." Journal of clinical oncology 23.21 (2005): 4602-4608.
(cited by 572) Bajorin, Dean F., et al. "Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy." Journal of Clinical Oncology 17.10 (1999): 3173-3181.
(cited by 511) Bellmunt, Joaquim, et al. "Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract." J Clin Oncol 27.27 (2009): 4454-61.
(cited by 467) Bellmunt, Joaquim, et al. "Pembrolizumab as second-line therapy for advanced urothelial carcinoma." New England Journal of Medicine 376.11 (2017): 1015-1026.
(cited by 471) Sternberg, Cora N., et al. "M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium." The Journal of urology 139.3 (1988): 461-469.
**first detailed report of effective chemo regime in bladder ca
(cited by 450) Bellmunt, Joaquim, et al. "Pembrolizumab as second-line therapy for advanced urothelial carcinoma." New England Journal of Medicine 376.11 (2017): 1015-1026.
(cited by 371) Balar, Arjun V., et al. "Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial." The Lancet 389.10064 (2017): 67-76.
(cited by 366) De Santis, Maria, et al. "Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986." Journal of clinical oncology 30.2 (2012): 191.
(cited by 320) Sharma, Padmanee, et al. "Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial." The Lancet Oncology 18.3 (2017): 312-322.
(cited by 267) Bellmunt, Joaquim, et al. "Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987." Journal of Clinical Oncology 30.10 (2012): 1107.
(cited by 227) Oliver, R. Timothy D., et al. "A randomised trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates (MRC TE19, EORTC 30982, ISRCTN27163214)." J Clin Oncol (2008).
(cited by 218) Bellmunt, Joaquim, et al. "Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens." Journal of Clinical Oncology 28.11 (2010): 1850-1855.
(cited by 212) Bellmunt, J., et al. "Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium." Journal of clinical oncology 18.18 (2000): 3247-3255.
(cited by 187) Galsky, Matthew D., et al. "Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy." Journal of Clinical Oncology 29.17 (2011): 2432-2438.
(cited by 134) Dodd, Paul M., et al. "Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma." Journal of clinical oncology 17.8 (1999): 2546-2546.
(cited by 116) Balar, Arjun V., et al. "First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study." The Lancet Oncology 18.11 (2017): 1483-1492.
(cited by 1093) von der Maase, Hans, et al. "Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer." Journal of clinical oncology 23.21 (2005): 4602-4608.
(cited by 572) Bajorin, Dean F., et al. "Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy." Journal of Clinical Oncology 17.10 (1999): 3173-3181.
(cited by 511) Bellmunt, Joaquim, et al. "Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract." J Clin Oncol 27.27 (2009): 4454-61.
(cited by 467) Bellmunt, Joaquim, et al. "Pembrolizumab as second-line therapy for advanced urothelial carcinoma." New England Journal of Medicine 376.11 (2017): 1015-1026.
(cited by 471) Sternberg, Cora N., et al. "M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium." The Journal of urology 139.3 (1988): 461-469.
**first detailed report of effective chemo regime in bladder ca
(cited by 450) Bellmunt, Joaquim, et al. "Pembrolizumab as second-line therapy for advanced urothelial carcinoma." New England Journal of Medicine 376.11 (2017): 1015-1026.
(cited by 371) Balar, Arjun V., et al. "Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial." The Lancet 389.10064 (2017): 67-76.
(cited by 366) De Santis, Maria, et al. "Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986." Journal of clinical oncology 30.2 (2012): 191.
(cited by 320) Sharma, Padmanee, et al. "Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial." The Lancet Oncology 18.3 (2017): 312-322.
(cited by 267) Bellmunt, Joaquim, et al. "Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987." Journal of Clinical Oncology 30.10 (2012): 1107.
(cited by 227) Oliver, R. Timothy D., et al. "A randomised trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates (MRC TE19, EORTC 30982, ISRCTN27163214)." J Clin Oncol (2008).
(cited by 218) Bellmunt, Joaquim, et al. "Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens." Journal of Clinical Oncology 28.11 (2010): 1850-1855.
(cited by 212) Bellmunt, J., et al. "Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium." Journal of clinical oncology 18.18 (2000): 3247-3255.
(cited by 187) Galsky, Matthew D., et al. "Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy." Journal of Clinical Oncology 29.17 (2011): 2432-2438.
(cited by 134) Dodd, Paul M., et al. "Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma." Journal of clinical oncology 17.8 (1999): 2546-2546.
(cited by 116) Balar, Arjun V., et al. "First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study." The Lancet Oncology 18.11 (2017): 1483-1492.
BLADDER RADIATION
(cited by 456) James, Nicholas D., et al. "Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer." New England Journal of Medicine 366.16 (2012): 1477-1488.
ADJUVANT THERAPY
Bajorin, Dean F., et al. "Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma." New England Journal of Medicine 384.22 (2021): 2102-2114.